Aerie Pharmaceuticals Inc. – ‘10-Q’ for 6/30/22 – ‘EXCEL’

On:  Thursday, 8/4/22, at 6:35pm ET   ·   As of:  8/5/22   ·   For:  6/30/22   ·   Accession #:  1337553-22-33   ·   File #:  1-36152

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    743K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     24K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
11: R1          Cover                                               HTML     71K 
12: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML    120K 
13: R3          Condensed Consolidated Balance Sheets (Unaudited)   HTML     36K 
                (Parenthetical)                                                  
14: R4          Condensed Consolidated Statements of Operations     HTML     91K 
                and Comprehensive Loss (Unaudited)                               
15: R5          Condensed Consolidated Statements of Stockholders'  HTML    117K 
                (Deficit) Equity (Unaudited)                                     
16: R6          Condensed Consolidated Statements of Cash Flows     HTML     88K 
                (Unaudited)                                                      
17: R7          The Company                                         HTML     46K 
18: R8          Significant Accounting Policies                     HTML     42K 
19: R9          Revenue Recognition                                 HTML     54K 
20: R10         Investments                                         HTML     73K 
21: R11         Fair Value Measurements                             HTML     72K 
22: R12         Inventory                                           HTML     27K 
23: R13         Property, Plant and Equipment, Net                  HTML     33K 
24: R14         Leases                                              HTML     22K 
25: R15         Accrued Expenses and Other Current Liabilities      HTML     31K 
26: R16         Debt                                                HTML     53K 
27: R17         Stock-Based Compensation                            HTML     78K 
28: R18         Commitments and Contingencies                       HTML     29K 
29: R19         Significant Accounting Policies (Policies)          HTML     39K 
30: R20         Significant Accounting Policies (Tables)            HTML     34K 
31: R21         Revenue from Contract with Customer (Tables)        HTML     34K 
32: R22         Investments (Tables)                                HTML     71K 
33: R23         Fair Value Measurements (Tables)                    HTML     71K 
34: R24         Inventory (Tables)                                  HTML     27K 
35: R25         Property, Plant and Equipment, Net (Tables)         HTML     32K 
36: R26         Accrued Expenses and Other Current Liabilities      HTML     31K 
                (Tables)                                                         
37: R27         Debt (Tables)                                       HTML     41K 
38: R28         Stock-Based Compensation (Tables)                   HTML     77K 
39: R29         The Company (Details)                               HTML     47K 
40: R30         Significant Accounting Policies - Additional        HTML     32K 
                Information (Details)                                            
41: R31         Significant Accounting Policies - Computation of    HTML     33K 
                Diluted EPS (Details)                                            
42: R32         Revenue Recognition - Narrative (Details)           HTML     65K 
43: R33         Revenue Recognition - Deferred Revenue, Noncurrent  HTML     36K 
                (Details)                                                        
44: R34         Investments - Cash, Cash Equivalents and            HTML     64K 
                Investments (Details)                                            
45: R35         Investments - Additional Information (Details)      HTML     23K 
46: R36         Fair Value Measurements - Fair Value Measurements   HTML     66K 
                (Details)                                                        
47: R37         Fair Value Measurements - Additional Information    HTML     22K 
                (Details)                                                        
48: R38         Inventory (Details)                                 HTML     31K 
49: R39         Property, Plant and Equipment, Net - Property,      HTML     40K 
                Plant and Equipment (Details)                                    
50: R40         Leases - Narrative (Details)                        HTML     35K 
51: R41         Accrued Expenses and Other Current Liabilities      HTML     32K 
                (Details)                                                        
52: R42         Debt - Narrative (Details)                          HTML     77K 
53: R43         Debt - Convertible Debt (Details)                   HTML     34K 
54: R44         Debt - Interest Expense of Convertible Notes        HTML     33K 
                (Details)                                                        
55: R45         Stock-Based Compensation - Stock-based              HTML     29K 
                Compensation Expense (Details)                                   
56: R46         Stock-Based Compensation - Additional Information   HTML     77K 
                (Details)                                                        
57: R47         Stock-Based Compensation - Stock Options Activity   HTML     64K 
                (Details)                                                        
58: R48         Stock-Based Compensation - Restricted Stock         HTML     49K 
                Activity (Details)                                               
59: R49         Stock-Based Compensation - Stock Appreciation       HTML     55K 
                Rights (Details)                                                 
60: R50         Commitments and Contingencies - Additional          HTML     52K 
                Information (Details)                                            
63: XML         IDEA XML File -- Filing Summary                      XML    112K 
61: XML         XBRL Instance -- aeri-20220630_htm                   XML   1.58M 
62: EXCEL       IDEA Workbook of Financial Reports                  XLSX     87K 
 7: EX-101.CAL  XBRL Calculations -- aeri-20220630_cal               XML    148K 
 8: EX-101.DEF  XBRL Definitions -- aeri-20220630_def                XML    508K 
 9: EX-101.LAB  XBRL Labels -- aeri-20220630_lab                     XML   1.32M 
10: EX-101.PRE  XBRL Presentations -- aeri-20220630_pre              XML    789K 
 6: EX-101.SCH  XBRL Schema -- aeri-20220630                         XSD    128K 
64: JSON        XBRL Instance as JSON Data -- MetaLinks              344±   487K 
65: ZIP         XBRL Zipped Folder -- 0001337553-22-000033-xbrl      Zip    262K 

‘EXCEL’   —   IDEA Workbook of Financial Reports

This is an IDEA Workbook.

Download this Microsoft® Excel® .xlsx workbook

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/07/22  Aerie Pharmaceuticals Inc.        DEFM14A                1:4.2M                                   Broadridge Fin’l So… Inc
 9/21/22  Aerie Pharmaceuticals Inc.        PREM14A     9/21/22    2:4.2M                                   Broadridge Fin’l So… Inc